![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Showing 2 trials matching your filters.
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib... Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglo...
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
DRUG: Ibrutinib
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Rituximab
DRUG: Venetoclax
This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 (sonrotoclax) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previousl...
DRUG: BGB-11417
DRUG: Zanubrutinib
Get the latest thought leadership on your Waldenström's Macroglobulinemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811